Researchers tested a novel antibody-drug conjugate known as trastuzumab deruxtecan in an expansion cohort of a phase I study of patients with advanced HER2+ breast cancer previously treated with trastuzumab emtansine.
A trial compared two intraperitoneal chemotherapy regimens and an intravenous regimen for newly diagnosed advanced ovarian carcinoma.
Researchers tested whether certain patients with HER2-positive breast cancer may eventually be eligible for non-surgical management.
Researchers looked at the use and effects of 5α-reductase inhibitors to treat benign prostatic hyperplasia on prostate cancer outcomes.
Final results of LATITUDE confirm the benefit of abiraterone acetate plus prednisone along with ADT in high-risk metastatic castration-sensitive prostate cancer.
The long-term results of the phase III HannaH trial confirmed the similarity between the subcutaneous and intravenous formulation of trastuzumab in patients with HER2+ breast cancer.
Researchers tested omitting chemotherapy from a treatment regimen involving dual blockade with pertuzumab and trastuzumab in patients with metastatic HER2+ breast cancer.
Researchers will discuss new findings on continuous vs intermittent chemotherapy schedules in advanced breast cancer at the ESMO Breast Cancer Congress.
Researchers tested whether TP53 mutation status can determine the function of estrogen receptor-beta (ESR2) in patients with triple-negative breast cancer.
A study of genetic testing in ovarian and breast cancer patients found substantial disparities in testing rates for ovarian cancer patients.